ОбзорГрафикТехническийНовости
Деривативы
TraderScreen

Cellectis SA/  FR0010425595  /

Euronext - Paris
08.11.2024  17:35:22 Изменение +0.022 Объем сделки Бид17:40:00 Предложение17:40:00 Максимум Минимум
1.710EUR +1.30% 20,226
Оборот: 34,218.274		 1.674Величина цены спроса: 153 1.718Величина цены предложения: 33 1.714 1.672
GlobeNewswire 26.08 Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Rec...
GlobeNewswire 08.08 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First...
GlobeNewswire 07.08 Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update 
GlobeNewswire 07.08 Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
GlobeNewswire 06.08 Cellectis Provides Financial Results for the Second Quarter 2024
GlobeNewswire 01.08 FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
GlobeNewswire 25.07 FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product c...
GlobeNewswire 16.07 Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as D...
GlobeNewswire 01.07 Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase ...
GlobeNewswire 28.06 Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
GlobeNewswire 20.06 Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
GlobeNewswire 20.06 Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cem...
GlobeNewswire 12.06 Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
GlobeNewswire 04.06 Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients wi...
GlobeNewswire 29.05 Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
GlobeNewswire 28.05 Cellectis Reports Financial Results for First Quarter 2024
GlobeNewswire 27.05 Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
GlobeNewswire 13.05 Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
GlobeNewswire 09.05 Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
GlobeNewswire 06.05 Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
GlobeNewswire 02.05 Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
GlobeNewswire 29.04 Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
GlobeNewswire 26.04 Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advan...
GlobeNewswire 22.04 Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene...
GlobeNewswire 10.04 Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Dis...